Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Status:	Terminated
Conditions:	Schizophrenia
Therapuetic Areas:	Psychiatry / Psychology
Healthy:	No
Age Range:	18 - 99
Updated:	12/22/2017
Start Date:	November 2007
End Date:	February 18, 2008

A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia

To assess the efficacy and safety of an investigational compound PF-02545920 for the
treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing
symptoms associated with schizophrenia.

Inclusion Criteria:

1. Have a current diagnosis of schizophrenia.

2. Increase in symptoms over the past 2-4 weeks.

3. Willing to remain inpatients for the duration of the trial.

Exclusion Criteria:

1. Evidence or history of clinically significant medical problems.

2. Females of childbearing potential.

3. A primary psychiatric diagnosis other than schizophrenia.

4. A diagnosis of substance abuse or dependence in the last 6 months.

We found this trial at

sites

Glendale Adventist Medical Center

Glendale, California 91206

from

Glendale, CA